20:57 , Aug 5, 2019 |  BC Extra  |  Company News

Takeda latest to partner with Sosei Heptares in GPCR discovery deal

In its second deal in the past month, Sosei partnered with Takeda to discover, develop and commercialize small molecules and biologics against multiple undisclosed G protein-coupled receptor targets. Sosei Group Corp. (Tokyo:4565) is eligible to...
23:31 , Jul 16, 2019 |  BC Extra  |  Company News

Genentech adds three discovery partnerships to build out pipeline

Through a trio of deals with Convelo, Skyhawk and Sosei Heptares announced Tuesday, Genentech is adding programs that could refresh its early stage neurology pipeline, as well as its oncology and other early R&D. Global...
22:41 , Jun 20, 2019 |  BC Innovations  |  Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

A new crop of companies is creating tools to systematize development of allosteric protein inhibitors, finally moving industry beyond the one-off compounds that have been found by accident. Allosteric pockets on proteins have long been...
16:59 , Jun 18, 2019 |  BC Innovations  |  Distillery Therapeutics

APLN17 analog identified for abdominal aortic aneurysm

DISEASE CATEGORY: Cardiovascular INDICATION: Aneurysm An analog of APLN17 could help treat abdominal aortic aneurysm (AAA). Levels of APLN, which is processed into APLN17 and other APLN peptides, were higher in diseased aorta from AAA...
00:12 , May 31, 2019 |  BC Innovations  |  Translation in Brief

New target for Oncoceutics' GPCR-targeting compounds

Two academic teams have discovered Oncoceutics’ GPCR-targeting products kill cancer via an alternative mechanism: triggering apoptosis by activating a mitochondrial protease. Oncoceutics Inc. is developing a pipeline of imipridones to antagonize or agonize GPCRs including...
17:02 , May 23, 2019 |  BC Extra  |  Financial News

How Bicycle, Ideaya fared in debuts as they join 2019’s growing IPO class

A pair of newly listed biotechs trended in opposite directions during first-day trading Thursday. Bicycle slipped 14% after pricing its IPO at the bottom end of its proposed range, while Ideaya was up 12% after...
10:57 , May 7, 2019 |  BioCentury  |  Finance

Confo’s €30M growth plan

Two pharma deals and early preclinical data from Confo’s GPCR-modulating compounds persuaded BioGeneration and Wellington to make their first investments in a company targeting G protein-coupled receptors. A €30 million ($33.6 million) series A round,...
02:16 , Apr 5, 2019 |  BC Innovations  |  Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
01:42 , Mar 1, 2019 |  BC Week In Review  |  Clinical News

Brilinta reduces CV events in patients without prior heart attack, stroke

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Brilinta ticagrelor met the primary endpoint of reducing major adverse cardiovascular events (MACE) in the Phase III THEMIS trial in patients with coronary artery disease and Type II diabetes with...